What would count as a real answer?

Does that study apply here?

Match the claim to the product

FDA means the Food and Drug Administration. Approval applies to a specific medicine; a research claim about another version is a different question.

Ask whether the study tested the same ingredient, the same tablet or injection, and the same health problem. Was it in people? What did it compare? What did it actually measure? Keep the answers in ordinary words.

Compounded means prepared to order. As of September 2026, a generic has its own FDA approval as a version of a brand-name medicine. A made-to-order drug does not have that approval.

As of September 2026, FDA calls it misleading to describe a made-to-order drug as a generic. It also calls it misleading to say the drug is proven to give the same result as an approved medicine.

How compounding decisions take shape

A meeting is a step in a process

A pharmacy preparing an individual patient’s medicine can use FDA’s compounding ingredient list as one route to meeting federal rules. As of September 2026, an ingredient can also qualify through an applicable official drug standard or use in an approved medicine. If neither applies, it needs to be on the compounding ingredient list. The finished medicine still has no FDA approval merely because its ingredient appears on that list.

An advisory committee gives FDA advice. As of September 2026, its vote alone does not change the law. Changing the compounding ingredient list requires FDA to put forward a rule, invite public comments, and then reach a final decision.

At the July 2026 meeting, the committee discussed semax, epitalon, emideltide, MOTS-c, TB-500, KPV, and BPC-157. If one of those names is on your offer, the meeting alone did not make it lawful to compound.

As of September 2026, FDA had published no written summary, verbatim account, or official vote record for the committee’s July 2026 peptide meeting. FDA staff had recommended keeping the peptides discussed there off the compounding ingredient list.

People and organisations that asked FDA to consider ingredients for compounding later withdrew some of those requests. As of September 2026, FDA still lists concerns beside those ingredients, including BPC-157, CJC-1295, and injectable GHK-Cu. Withdrawing a request does not mean FDA has cleared the ingredient or approved it.

FDA’s concerns include unwanted material and clumping in some peptide products that may make the body’s defences react to them. Studies in people may be missing or too limited to show whether they cause harm.

If an offer relies on that meeting or a withdrawn request, ask what rule actually allows the exact product to be made. Ask the person writing the prescription what is known, what remains uncertain, and what that means for your care.